ISTH 2021 Congress Archives - ISTH Congress Abstracts

Abstract Number: PB0414

EACA Loaded Platelets Sustain Clots More Efficiently then Free EACA

S. Xu¹, D. Sheik¹, K. Moskowitz¹
Abstract Number: OC 29.1

Early Endosomal GTPase Rab5 Regulates GPIb Trafficking and Platelet Production in vitro

I. Bertović¹, R. Kurelić¹, H. Mahmutefendić Lučin², A. Jurak Begonja¹
Abstract Number: PO100

Early Stage Atherosclerosis Regression, Using High-dose Atorvastatin Administration Accompanied by B-mode Ultrasound-guided 5-aminolevulinic Acid-mediated Catheter-based Low Level Blue Laser Photodynamic Therapy

H. Mehrad^1,2, A. sultan-Qurraie³
Abstract Number: PB1181

Echocardiographic Parameters Predicted Short-term Outcomes in Acute Pulmonary Embolism

D. Nadejda¹, T. Cuzor¹
Abstract Number: PB0361

Effect and Stability of Dabigatran on Thrombin Generation over a Year in Elderly Patients with Atrial Fibrillation

T.R. Rocha¹, A. Pastana², P. Villaça¹, E. D`Amico¹, P. Yu², I. Magalhães², F.A. Cardozo², G. Lustosa³, L. Franco³, B. Caramelli², D. Calderaro²
Abstract Number: PB0420

Effect of Alpha2-plasmin Inhibitor C-terminal Forms on in vitro Clot Lysis

B. Baráth¹, R. Orbán-Kálmándi¹, Z. Bagoly¹, É. Katona¹
Abstract Number: PB0993

Effect of Antiplatelet Therapy on Monocyte-Platelet Aggregates

C.C. Rolling¹, K. Myndzar¹, H. El Bannoudi¹, T. Schwartz¹, T.J. Barrett¹, J.S. Berger^1,2
Abstract Number: PB0770

Effect of Aroma Hand Massage on the Plasma Concentration of Plasminogen Activator Inhibitor-1 Produced by Endothelial Cells in Healthy Subjects

T. Hayashi¹, N. Akita², A. Tamada¹
Abstract Number: PB0231

Effect of Dexamethasone on Direct Oral Anticoagulant Plasma Levels in Patients with COVID-19

F. Bosch^1,2, M. Candeloro³, N. Potere³, E. Porreca³, M. Di Nisio³, P.W. Kamphuisen^1,2
Abstract Number: PB0392

Effect of Edoxaban on Laboratory Methods

H. von Horn^1,2, L. Bui³, A. Rasmuson^1,2, J. Douxfils⁴, J. Harenberg^5,6, J. Antovic^1,2, K. Christensen³
Abstract Number: PB0407

Effect of Flow and Shear Rate on Structural Properties and Fibrinolysis of the Fibrin Network

J.J. de Vries¹, I. El-Idrioui¹, D.C. Rijken¹, M.P. de Maat¹.
Abstract Number: PB1053

Effect of Hydroxychloroquine on the Levels of Inflammatory Cytokines and Tissue Factor in Patients with Primary Antiphospholipid Syndrome

B. Mazetto¹, S. Saraiva², B. Jacintho², G. Vieira-Damiani^3,1, C. Vaz², J.D. Oliveira², A.P. dos Santos⁴, G. Mesquita⁴, J. Annichino-Bizzacchi^2,5, F. Orsi^5,6
Abstract Number: PB0369

Effect of NETS from Different Models on Fibrin Polymerization Profile and Coagulation-fibrinolysis Balance

N.M.-b. Biatougou¹, F. Mas², B. Montpellier², S. Mirshahi¹, J. Soria³, G. Contant¹
Abstract Number: PB0762

Effect of Social Stress on Innate Immune Activation in an SIV-infected Pigtail Macaque (Macaca nemestrina) Model of Acute HIV Infection

N. Castell¹, S. Guerrero-Martin^1,2, E.N. Shirk¹, L.H. Ruben¹, S.E. Queen¹, M. Li¹, B. Bullock¹, D. Graham¹, M.C. Zink¹, L. Gama^1,3, R.J. Adams¹, J.E. Clements¹, J.L. Mankowski¹, K.A. Metcalf Pate^1,2
Abstract Number: PB1131

Effect of Therapy on Thrombin Generation in Patients with Polycythemia Vera

N. Silina¹, N. Korsakova¹, O. Golovina¹, O. Matvienko¹, M. Fominykh¹, E. Efremova¹, S. Voloshin¹, L. Papayan¹
Abstract Number: PB0386

Effect of Warfarin on Thrombin Generation Parameters in Elderly Patients with Atrial Fibrillation

T.R. Rocha¹, A. Pastana², E. D`Amico¹, P. Villaça¹, P. Yu², I. Magalhães², F.A. Cardozo², L. Franco³, G. Lustosa³, B. Caramelli², D. Calderaro²
Abstract Number: OC 76.3

Effectiveness and Safety of Apixaban vs Warfarin among Venous Thromboembolism Patients Using Five US Databases: A Subgroup Analysis of Thrombophilia

A. Cohen¹, J. Sah², A. Dhamane³, T. Lee⁴, L. Rosenblatt³, P. Hlavacek⁴, B. Emir⁴, A. Keshishian², R. Delinger², X. Luo⁵
Abstract Number: OC 57.4

Effectiveness and Safety of Concomitant Use of Direct Oral Anticoagulants and Antiplatelet Agents among Patients with Venous Thromboembolism: A Population-based Multinational Cohort Study

A. Douros¹, F. Basedow², Y. Cui³, D. Enders², V. Tagalakis¹
Abstract Number: PB1079

Effectiveness and Safety of Direct Oral Anticoagulants in Thai Patients with Atrial Fibrillation

S. Srikajornlarp¹, K. Boonyawat¹, P. Angchaisuksiri¹, K. Likittanasombat¹, M. Amnueypol¹, P. Numthavaj¹, P. Vathesatogkit¹
Abstract Number: PB1245

Effectiveness and Safety of DOACs for the Prevention of Recurrent VTE: A Prospective Cohort Study

A. Vinci¹, M.C. Vedovati¹, M.G. De Natale¹, L. Pierpaoli², F. Di Filippo², G. Agnelli¹, C. Becattini¹
Abstract Number: PB0634

Effectiveness, Safety and Cost Assessment of Emicizumab in Clinical Practice

A. Riera¹, A. Plaza¹, N. Pagès¹, M. Masip¹, P. Riera¹, M. Carrasco¹, J. Mateo¹, N. Vilalta¹
Abstract Number: PB0207

Effects of Dalteparin on Anti-Xa Levels Cannot Be Predicted in Critically Ill COVID-19 Patients

C. van der Heijden¹, E. Kooistra¹, R. ter Heine¹, R. Brüggemann¹, J. Walburgh Schmidt¹, E. de Grouw¹, T. Frenzel¹, P. Pickkers¹, J. Leentjens¹
Abstract Number: LPB0034

Effects of Depression and Antidepressant Use on Platelet Reactivity Traits

J. Grech¹, M. Chan^1,2, A. Lachapelle¹, F. Thibord¹, Z. Schneider¹, P. Armstrong², C. Wallace de Melendez¹, T. Warner², M.-H. Chen¹, A. Johnson¹
Abstract Number: PB0975

Effects of Different Concentrations of Apixaban Combined with Antiplatelet Therapies on Platelet Hemostatic and Thrombogenic Functions. Ex-vivo Exploratory Study in Patients under Various Antiplatelet Regimens

J. Martinez-Sanchez^1,2,3, L. Castrillo⁴, D. Jerez², S. Torramade-Moix², M. Palomo^1,2,3, G. Mendieta⁴, M. Diaz-Ricart^2,3, M. Roque⁴, G. Escolar^2,3
Abstract Number: LPB0012

Effects of Liraglutide vs. Lifestyle Changes on sST2 and Galectin-3 in Obese Subjects with Prediabetes or Type 2 Diabetes after Comparable Weight Loss

R. Tripaldi¹, P. Simeone¹, R. Liani¹, S. Ciotti¹, A.E. Michelsen², B. Halvorsen², T. Ueland², P. Aukrust², A. Consoli¹, F. Santilli¹
Abstract Number: PB0467

Effects of von Willebrand Factor on Plasma Haemostasis

C. Kluft¹, K. Van Leuven¹, C. Krijnen¹, P. De Kruijf¹
Abstract Number: PB0538

Efficacy and Safety Analysis of the Use of rIX-FP in Patients with Hemophilia B: A Prospective, Non-interventional, Surveillance Study from Germany

J. Oldenburg¹, S. Holzhauer², S. Wenning³, M. Olivieri⁴, C. Pfrepper⁵
Abstract Number: PB1279

Efficacy and Safety Comparison of DOACs versus Enoxaparin or Heparin with Concomitant Warfarin in Patients with Acute Venous Thromboembolism – A Systematic Review and Meta-analysis

I. Rinaldi¹, K. Winston², J. Leoni², Y. Samudera²
Abstract Number: OC 69.2

Efficacy and Safety of Dabigatran in the Treatment and Secondary Prevention of Venous Thromboembolism in Children with Central Line or Implantable Device–related Thrombosis

M. Albisetti¹, I. Tartakovsky², J. Halton³, L. Bomgaars⁴, E. Chalmers⁵, L. Mitchell⁶, M. Luciani⁷, I. Nurmeev⁸, K. Gorbatikov⁹, I. Gergei^2,10, E. Kleine¹¹, M. Brueckmann^2,10, L. Brandão^12,13
Abstract Number: PB0787

Efficacy and Safety of Dabigatran in the Treatment and Secondary Prevention of Venous Thromboembolism in Children with Cerebral Venous and Sinus Thrombosis

L. Brandão^1,2, I. Tartakovsky³, J. Halton⁴, L. Bomgaars⁵, E. Chalmers⁶, L. Mitchell⁷, M. Luciani⁸, I. Gergei^3,9, E. Kleine¹⁰, M. Brueckmann^3,9, M. Albisetti¹¹
Abstract Number: PO176

Efficacy and Safety of Direct Oral Anticoagulants in Morbidly Obese Patients with Acute Venous Thromboembolism: A Meta-analysis

B. Borea¹, M. Righini¹
Abstract Number: PB1074

Efficacy and Safety of Direct Oral Anticoagulants in Patients of Southern Italy with Atrial Fibrillation: Real-world Data from the EGINA Registry

N. Ciavarella¹, A. Ciampa², S. Bradamante³, A. Colucci⁴, G. Dirienzo⁵, A.M. Iannone⁶, G. Polimeno⁷, G. Rescigno⁸, L. Ria⁹, R. Scarafile¹⁰, A. Ciavarella¹¹, C. Custodero¹², C. Sabbà¹²
Abstract Number: PB0830

Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia: ADVANCE SC, a Global Phase 3 Clinical Trial in Progress

C. Broome¹, V. McDonald², S. Jain³, S. Babu⁴, E. Oliva⁵, W. Parys⁶, A. Hultberg⁶, K. De Beuf⁶, D. Gandini⁶, Y. Miyakawa⁷, W. Ghanima⁸
Abstract Number: PB0511

Efficacy and Safety of Emicizumab Prophylaxis in Severe Haemophilia A without Inhibitors: A Report from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)

C. Wall¹, H. Xiang², B.P Palmer², E. Chalmers³, P. Chowdary⁴, P.W Collins⁵, S. Fletcher⁶, D.P Hart⁷, G.W Hall⁸, R. Liesner⁹, S. Shapiro⁶, D. Stevensen¹⁰, K. Talks¹¹, C.RM Hay¹, United Kingdom Haemophilia Centre Doctors' Organisation
Abstract Number: LPB0070

Efficacy and Safety of Human Fibrinogen Concentrate for Treatment of on-demand Bleeding in Adolescent and Pediatric Patients with Congenital Fibrinogen Deficiency: Results from the FORMA-02 and FORMA-04 Clinical Trials

C. Djambas-Khayat^1,2, S. Lohade³, F. D'Souza⁴, L. Shamanur⁵, O. Zekavat⁶, I. Kruzhkova⁷, B. Schwartz⁸, C. Solomon⁷, F. Peyvandi^9,1
Abstract Number: OC 49.3

Efficacy and Safety of Intraarticular Injection of Mononuclear Stem Cells in Hemophilia Patients with Arthropathy

M. Karimi¹, A. Shahsavani¹, M. Ayatollahi², S. Haghpanah¹, M. Tahami², P. Iranpour³, M. Bordbar¹, H. Tavoosi⁴, S. Azizkhani⁵, F. Amirmoezi¹
Abstract Number: PB0524

Efficacy and Safety of rIX-FP: A Longitudinal Analysis of Patients Treated across the PROLONG-9FP Clinical Trials Program

I. Pabinger¹, T. Lissitchkov², A. Nagao³, L.M. Lepatan⁴, Y. Li⁵, W. Seifert⁶, M.E. Mancuso^7,8
Abstract Number: OC 26.1

Efficacy and Safety of Valoctocogene Roxaparvovec Adeno-associated Virus Gene Transfer for Severe Hemophilia A: Results from the Phase 3 GENEr8-1 Trial

M.C Ozelo¹, J. Mahlangu², KJ. Pasi³, A. Giermasz⁴, A.D Leavitt⁵, M. Laffan⁶, E. Symington⁷, D.V Quon⁸, J.-D. Wang⁹, K. Peerlinck¹⁰, S. Pipe¹¹, B. Madan¹², N.S Key¹³, G.F Pierce¹⁴, B. O’Mahony^15,16, R. Kaczmarek^17,18, A. Lawal¹⁹, M. Huang¹⁹, W.Y. Wong¹⁹, B. Kim¹⁹, GENEr8-1 Trial Group
Abstract Number: PB0934

Efficacy of hFVIII/VWF Concentrate in Pediatric Patients with von Willebrand Disease (VWD): The French Experience

A. Harroche¹, L. Rugeri², R. D'Oiron³, A. Hassoun⁴, Y. Repesse⁵, B. Frotscher⁶, A. Fournel⁷, D. Bracquart⁸, C. Martin⁸, M. Trossaert⁹, S. Meunier²
Abstract Number: LPB0068

Efficacy of Parenteral Formulations of Desmopressin in the Treatment of Bleeding Disorders: A Systematic Review

S. McKinlay¹, S. Sreeraman¹, O. Motalo¹, A. Li², M. Crowther¹
Abstract Number: PO186

Efficacy of Preoperative Prevention in Venous Thromboembolism at Endoscopic Urological Interventions

E. Shorikov¹, P. Shorikov¹, D. Shorikova¹
Abstract Number: PB0567

Efficacy of Reduced-dose Emicizumab in Haemophilia A with Inhibitors: Real World Experience in East Malaysia

A.S.O. Tang¹, T.S. Leong¹, C.T. Ko¹, L.P. Chew¹
Abstract Number: PB0434

Efficacy of Rituximab for the Treatment of Acquired Hemophilia A: A Systematic Review

S. Moonla¹, A. Suriyasathaporn¹, K. Kiatsoonthon¹, C. Chai-Adisaksopha^1,2
Abstract Number: PB0590

Efficacy of Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia A: Final Results from the NuProtect Study

E.J. Neufeld¹, R.J. Liesner²
Abstract Number: PB0241

Efficiency of Anticoagulant Protein C System in Patients with Coronavirus Infection Caused by the SARS-CoV-2

O. Matvienko¹, N. Korsakova¹, A. Lerner², T. Shvedova², L. Papayan¹, O. Golovina¹
Abstract Number: PB1041

Elevated Circulating Endothelial Cells and Success in Endothelial Colony-forming Cells Isolation

L. Silva¹, A. Justo-Junior², S. Montalvão¹, R. Medina³, J. Annichino-Bizzacchi¹
Abstract Number: PB1187

Elevated D-dimer Levels and DVT Following Neurosurgery

M.T. Sartori¹, A. Bozzolin¹, G. Camporese², P. Ciccarino³, F. Boscaro¹, A. Rizzoli³, G. Avruscio², F. Fabris¹
Abstract Number: LPB0036

Elevated Platelet-derived sGPVI Is a Biomarker of Venous In-stent Stenosis in Patients with Post-thrombotic Syndrome

A.M. Gwozdz¹, S.A. Black¹, R. Morris¹, S. Messiha¹, M. Ikram¹, A.P. Bye², J.M. Gibbins², M.L. Rand³, A.S. Patel¹, B. Modarai¹, A. Smith¹, P. Saha¹
Abstract Number: OC 38.4

Elimination of Factor VIII Inhibitors by the IgG-degrading Enzyme of Streptococcus pyogenes

M. Bou-Jaoudeh¹, S. Delignat¹, V. Daventure¹, A. Mimoun¹, J. Astermark², S. Lacroix-Desmazes¹
Abstract Number: PB0741

Elucidating the Relationship between Thrombo-inflammatory Biomarkers and Blood Cellular Indices in Lymphoma Patients

M. Jaradeh¹, N. Baig¹, E. Bontekoe¹, D. Antic², J. Fareed¹
Abstract Number: PB0079

Elucidating Thrombus Formation in ECMO Circuits: A Detailed Histological Study

S. Staessens^1,2, M. Moussa^2,3, A. Pierarche⁴, E. Boulleaux², A. Ung², L. Desender¹, B. Pradines^2,5, N. Rousse^2,6, A. Duhamel⁴, A. Rauch^2,5, K. Vanhoorelbeke¹, D. Corseaux², S.F. De Meyer¹, S. Susen^2,5
Abstract Number: PB0778

Emergency Department Care in Pediatric and Adolescent Patients Presenting with Abnormal Uterine Bleeding

N. Kendel¹, J. Stanek¹, F. Haamid¹, J. Powers², S. O'Brien¹
Abstract Number: PB0889

Emergency Splenectomy for Immune Thrombocytopenia (ITP) Patients with Life-threatening Bleeding: A Report of Three Cases and Review of the Literature

M. Yang¹, Z. Zhou²
Abstract Number: PB0684

Emi and Me: The Real-world Impact of Emicizumab on the Lives of People with Haemophilia A with Inhibitors and their Families

S. Fletcher¹, M. Holland², K. Jenner², K. Khair²
Abstract Number: PB0681

Emicizumab Assays: One Stage vs. Chromogenic Stage Assay

M. Stuart¹, D. Chen¹, R. Pruthi¹
Abstract Number: PB0525

Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-friendly and Cost-efficient Regimen

L.H. Bukkems¹, K. Fischer², I. Kremer-Hovinga², A.A. Donners³, K. Fijnvandraat⁴, R.E. Schutgens², M.H. Cnossen⁵, R.A. Mathôt¹
Abstract Number: PB0595

Emicizumab in Acquired Hemophilia A: A Scoping Review

W. Shi¹, M. Crowther¹, K.(. Kim¹.
Abstract Number: PB0495

Emicizumab in Obese Adults with Hemophilia A – Pooled Data from Three Phase III Studies (HAVEN 1, 3 and 4)

M. Recht^1,2, J. Mahlangu³, M. Minhas⁴, B. Trzaskoma⁴, M. Shah⁴, G. Young⁵
Abstract Number: PB0565

Emicizumab in Pediatric Hemophilia: A Single-center Retrospective Study

C. Cohen¹, R. Diaz¹
Abstract Number: PB0606

Emicizumab in the Treatment of Adult Haemophilia Patients Real-world Data

J. Windyga¹, J. Zdziarska², E. Stefanska-Windyga³, E. Chmielewska⁴, K. Chojnowski⁵, M. Jamrozik⁶, J. Kozinska⁷, J. Rupa-Matysek⁸, G. Semenczuk⁹, E. Zarzycka¹⁰, A. Buczma¹
Abstract Number: OC 32.2

Emicizumab Prophylaxis and Monitoring: Real World Data

A.A. Barg¹, I. Budnik², E. Avishai¹, T. Brutman-Barazani¹, D. Bashari¹, M. Misgav¹, A. Lubetsky¹, A.A. Kuperman³, T. Livnat¹, G. Kenet¹
Abstract Number: PB0632

Emicizumab Therapy for Neonatal Intracranial Hemorrhage

A. Dunn^1,2
Abstract Number: PB0504

Emicizumab Treatment in Pediatric Haemophilia A Patients: >1 Year Safety Based on Real-world Data from the PedNet Cohorts

G. Kenet¹, B. Nolan², J. Oldenburg³, J. Motwani⁴, R. D' Oiron⁵, C. Male⁶, H. Chambost⁷, K. Fischer⁸, C. Van Geet⁹, H.M. van den Berg¹⁰, PedNet Study Group
Abstract Number: PB0602

Emicizumab: What Can Patients Expect Regarding Hemostasis, Bleeding and Sports Capacity?

B. Boulden Warren¹, D. Thornhill¹, L. Jacobson¹, C. Baird¹, D. Hill¹, C. Ng¹, T. Buckner¹, M. Wang¹, M. Manco-Johnson¹
Abstract Number: OC 49.2

Emicizumab: Will it Suffice for Bone Metabolism?

M. Manco-Johnson¹, N. Briones¹, A. Tran¹, D. Thornhill¹, C. Baird¹, L. Jacobson¹, B. Warren¹, S. Kuldanek¹, D. Ambruso¹, G. Karsenty²
Abstract Number: LPB0133

Endothelial Cell and Neutrophil Interactions Are Required for the Activation of the Blood Coagulation Cascade Leading to Thrombus Formation Following a Laser-induced Injury

E. Carminita¹, L. Crescence¹, N. Brouilly², L. Panicot-Dubois¹, C. Dubois¹
Abstract Number: PB0332

Endothelial Dysfunction in Patients with Ph-negative Myeloproliferative Neoplasms

N. Korsakova¹, O. Golovina¹, N. Silina¹, E. Efremova¹, L. Papayan¹
Abstract Number: PB1127

Endothelial Dysfunction in Patients with Polycythemia Vera on Cytoreductive and / or Antiplatelet Therapy

N. Silina¹, N. Korsakova¹, O. Golovina¹, M. Fominykh¹, E. Efremova¹, S. Voloshin¹, L. Papayan¹
Abstract Number: PB0745

Endothelial Protein C Receptor (EPCR)-dependent Sequestration of P. falciparum Erythrocyte Membrane Protein 1 (PfEMP1)-derived Fluorescent Microspheres in the Brain Vasculature of a Humanized Mouse

R. Aiolfi¹, P.J. Cowan², H. Gock², H. Weiler³, L. Turner⁴, T. Lavstsen⁴, L.O. Mosnier¹
Abstract Number: OC 70.3

Endothelial Targeting in the Treatment of Early Clinical Stages of COVID-19: Results of a Randomized Placebo-controlled Trial

A. Gonzalez Ochoa¹, J. Raffetto², A.G Hernandez Ibarra³
Abstract Number: PO114

Endothelin and General Oxidative Ability as Markers of Deadaptation in Sailors in the conditions of the Arctic Flight

N. Vorobyeva^1,2, A. Vorobyeva²
Abstract Number: PB1269

Enhancement of Thrombin Generation in Lymphoma Cohort by Andexanet Alfa

F. Siddiqui¹, E. Bontekoe¹, D. Antic¹, D. Hoppensteadt¹, G. Gerotziafas², I. Elalamy², J. Fareed¹
Abstract Number: LPB0106

Enhancing Transfusable Platelets Using mRNA Therapy to Produce Exogenous Proteins

J. Leung^1,2,3, C. Strong^1,2,3, A. Hagner⁴, K. Badior^1,2,3, D. Witzigmann¹, L.J. Juang^1,2,3, M. Robertson^1,2,3, E. Jan¹, P. Zandstra^2,4, P. Cullis¹, C. Kastrup^1,2,3
Abstract Number: PB0246

Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients (INHIXACOV19)

B. Cosmi¹, M. Giannella², C.M. Re³, F. Cristini⁴, E.G. Bignami⁵, A. Montineri⁶, S. Testa⁷, S. Casari⁸, E. Grandone⁹, R. Rozzini¹⁰, E. Tacconelli¹¹, A. Castagna¹², G. Di Perri¹³, M. Salvetti¹⁴, A. Stella¹⁵, P. Viale²
Abstract Number: LPB0082

Enrichment of Variants in Platelet Genes in Patients with Bleeding of Unknown Cause

M. Bowman¹, J. Grabell¹, A.D. Paterson², M.-C. Poon³, S. Jackson^4,5, D. Lillicrap⁶, G. Haller⁷, B. Sadler⁸, P. James¹
Abstract Number: PB0720

Epidemiology of Severe Rare Congenital Bleeding Disorders at a Bleeding Disorders Reference Center in Spain

M.F. Martinez Garcia¹, O. Benitez Hidalgo¹, I. Corrales Insa², S. Franco Palacios³, M. Fernandez Caballero⁴, M. Suito Alcantara⁵, V. Cortina Giner⁶, M. Gironella Mesa⁷, F. Bosch Albareda⁸
Abstract Number: LPB0063

Epigenome-wide Association Study of DNA Methylation in Blood and Circulating Fibrinogen Levels

J. Hahn¹, J. Bressler¹, M.R. Brown¹, M. Fornage^1,2, J. Bell³, D.I. Boomsma⁴, A. Dehghan⁵, A. Domingo-Relloso^6,7, X. Guo⁸, A.D. Johnson^9,10, M. Kleber¹¹, D.L. McCartney¹², P.-E. Morange¹³, N.L. Smith^14,15,16, A. Teumer¹⁷, W. Zhao¹⁸, A.C. Morrison¹, P.S. de Vries¹, CHARGE Epigenetics and Hemostasis Working Groups
Abstract Number: PB0544

Eptacog Beta (Factor VIIa, Recombinant) Provides Rapid Bleed Resolution and Pain Relief in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

W. Miesbach¹, C. Hermans², S.W. Pipe³, J. Journeycake⁴, J. Ducore⁵, M. Escobar⁶, M. Wang⁷, D. Quon⁸, L. Boggio⁹, N. Chambron¹⁰, A. AL-Sabbagh¹¹, D. Bonzo¹¹, C. Macie¹², I.S. Mitchell¹³, J. Mahlangu¹⁴
Abstract Number: PB1191

Erythrocytosis and Thromboembolic Events in Transgender Individuals Undergoing Masculinizing Therapy with Testosterone

M. Oakes¹, A. Arastu¹, C. Kato¹, J. Somers¹, H. Holly¹, G. Dy¹, T. Kohs¹, O. McCarty¹, V. Raghunathan¹, J. Shatzel¹
Abstract Number: PB0791

Essential Thrombocythemia in Children: A Retrospective, Real-world Study Conducted in China

R. Fu¹, D. Zhang¹, H. Li¹, F. Xue¹, X. Liu¹, Y. Chen¹, W. Liu¹, R. Yang¹, L. Zhang¹.
Abstract Number: PO151

Essential Thrombocythemia with Deep Vein Thrombosis and Recurrent Gangrene Pedis

H. Gustian¹.
Abstract Number: PB0393

Establishing Reference Values in Burkina Faso: A Study of Haemostasis Global Assays and Coagulation Factors Eight and Nine, Based on Blood Donors

K. Nebie^1,2, S. Sawadogo^1,2, j. Koulidiati^3,4, W. Ouedraogo¹, D. Kima⁵, M. Nikiema⁴, S. Sawadogo^6,7, D. Lasne⁸, A. Toure⁹, E. Kafando^1,5, GIH Study Group
Abstract Number: OC 12.3

Estimating Bleeding Risk in Patients with Cancer-associated Thrombosis: External Validation of Existing Risk Scores and Development of a New Risk Score

M.A. de Winter¹, J.A.N. Dorresteijn², W. Ageno³, C. Ay^4,5, J. Beyer Westendorf⁶, M. Coppens⁷, F.A. Klok⁸, F. Moustafa⁹, N. Riva¹⁰, P.C Ruiz Artacho^11,12,13, T. Vanassche¹⁴, M. Nijkeuter¹
Abstract Number: OC 36.2

Estimating the Causal Association between Body Mass Index and Platelet Properties: Evidence for a Positive Association with Immature Platelet Count

L. Goudswaard¹, L. Corbin¹, K. Burley¹, P. Akbari², A. Butterworth², N. Soranzo³, A. Mumford¹, N. Timpson¹, I. Hers¹
Abstract Number: PB0601

Estimation of Secondary Prophylaxis Effectiveness in Patients with Severe Form of Hemophilia A

T. Talako¹, H. Kuzmich², V. Zmachinsky¹, A. Uss²
Abstract Number: LPB0020

Etranacogene Dezaparvovec (AAV5-Padua hFIX Variant, AMT-061), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-severe Hemophilia B: 2.5 Year Data from a Phase 2b Trial

E. Gomez¹, A. Giermasz², G. Castaman³, N.S Key⁴, S.U Lattimore⁵, F.W. Leebeek⁶, W. Miesbach⁷, M. Recht⁵, A. von Drygalski⁸, E.K Sawyer⁹, S.W. Pipe¹⁰
Abstract Number: PB0578

Evaluating the Effectiveness of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Adolescents and Children with Hemophilia A in the Real World in Japan: Interim Analysis of the Multicenter, Observational Fc Adolescent and Children Treatment Study (FACTs)

M. Kobayashi¹, K. Nogami², Y.-D. Park³, M. Shiraishi⁴, M. Takatoku⁴, T. Matsushita⁵
Abstract Number: PB0067

Evaluation and Performance Characteristics of the Automated Sysmex CN-6000 Haemostasis Analyzer

I. Martin-Toutain¹, M. Gaaloul¹, M. Berber¹, E. Bailly¹, J.-P. Delorme², Y. Bourti², C. Frere^1,3
Abstract Number: PB1059

Evaluation of a Gene Signature Related to Thrombotic Manifestations in Antifospholipid Syndrome

B. Jacintho¹, B. Mazetto², B. Hounkpe³, A.P. Santos⁴, C. Vaz¹, G. Vechiatto⁴, J. Oliveira¹, E. de Paula^5,2, F. Orsi^5,6
Abstract Number: PB0353

Evaluation of a New Fully Automated ADAMTS13 Activity Assay

S. Geiter¹, L. Wagner¹, N. Binder¹, U. Budde²
Abstract Number: PB0052

Evaluation of a New Thromboplastin Reagent Containing Human Recombinant Tissue Factor for the Determination of Prothrombin Time Reagent: the (h)PT-Phen™ LRT

I. Martin-Toutain¹, M. Gaaloul¹, J.-P. Delorme², Y. Bourti², C. Frere^1,3
Abstract Number: PB0331

Evaluation of Activated Clotting Time (ACT) Results on a New POC Coagulation Analyzer

A. Leung¹, W. Lu¹, M. Martin¹, C. Smith¹, J. Diggs¹, S. Chen¹, P. Yu¹, R. Bottenus¹
Abstract Number: PB0884

Evaluation of an Automated Platelet Aggregation Method for the Detection of Patients with Congenital or Acquired Platelet Function Defects

A. Lecchi¹, S. La Marca¹, L. Padovan¹, M. Boscarino², A. Artoni¹, N. Arai³, S. Shinohara³, M. Capecchi⁴, F. Peyvandi^1,2
Abstract Number: PB0701

Evaluation of Coagulation Profile in FVII Deficiency with Inhibitor Using Global Coagulation Tests: A Case Report

M.I. Rivas Pollmar¹, E. Garcia Arias-Salgado¹, M.T. Alvarez Roman¹, E. Monzon Manzano¹, P. Acuña Butta¹, M. Martin Salces¹, S. Garcia Barcenilla¹, T. Cebanu¹, E. Gonzalez Zorrilla¹, N. Butta Coll¹, V. Jimenez Yuste¹
Abstract Number: PB0363

Evaluation of Effect of Extracorporeal Near-infrared Laser-mediated Photobiomodulation Therapy on Endothelial Dysfunction Improvement Using a New B-mode Ultrasound Image Processing Software-based Automatic Method

H. Mehrad^1,2, M. Farhoudi³
Abstract Number: PB1147

Evaluation of Fibrinogen Level In non-Diabetic Hypertensive Patients at the University of Nigeria Teaching Hospital Ituku-Ozalla

E. Ezigbo¹, O. Achunine², T. Nwagha³
Abstract Number: PB0723

Evaluation of FXI-deficiency Treatment in Pediatric Patients: A Case-series

D. Muzafar Gani^1,2, K. Strike^3,4, K. Decker⁴, T. Almonte⁴, M.D Bhatt^5,4, D. Matino^6,4, A.K. Chan^5,4
Abstract Number: LPB0013

Evaluation of Heparin-induced Thrombocytopenia Before and during the COVID-19 Pandemic at a US National Reference Laboratory

E. Wong¹, L. Worfolk¹, L. Noh¹, W. Wu¹, M. Sahud², F. Racke², J. Dlott¹
Abstract Number: PB0357

Evaluation of Intra-site and Inter-site Precision of PT Determination with STA-NeoPTimal on Start Max Semi-automated Instrument

G. Le Goff¹, M. Bouchain¹, L. Chaillet², J. Gautier³, V. Genty², S. Langlet¹, A. Carlo⁴, J. Beltran¹
Abstract Number: PB0532

Evaluation of Liver Health after Fidanacogene Elaparvovec Gene Therapy: Data from Study Participants with up to 5 Years of Follow-up

L.A. George^1,2, S.K. Sullivan³, J.E. Rasko⁴, A. Giermasz⁵, B.J. Samelson-Jones¹, J.M. Ducore⁵, J.M. Teitel⁶, C. E. McGuinn⁷, D. Rybin⁸, J.E. Murphy⁹, I. Winburn¹⁰, A. Chhabra⁹, J. Rupon¹¹
Abstract Number: PB0317

Evaluation of Oxidative Stress, Thrombosis, and Inflammation in Patients with End-stage Osteoarthritis

V. Jain¹, E. Bontekoe¹, F. Siddiqui¹, J. Liles¹, J. Fareed¹, W. Hopkinson¹
Abstract Number: PB1003

Evaluation of Platelet Dense Granules by Transmission Electron Microscopy (PTEM) in Pediatric Patients and Healthy Pediatric Donors

J. Greenmyer¹, D. Warad¹, K. Howell¹, K. Fischer^1,1, L. Stromback¹, T. Gibbons¹, J. Charlesworth¹, R. Barness¹, S. Gossman¹, J. Gamez¹, R. Pruthi¹, D. Chen¹
Abstract Number: PB0482

Evaluation of Primary Haemostasis in Children and Young Adults with Haemophilia

M. Kürschner¹, J. Lohse¹, F. Boiti¹, O. Tiebel², R. Knöfler¹
Abstract Number: PB0579

Evaluation of Real-world Effectiveness of BAY 81-8973 to Treat Hemophilia A: An Analysis within the ATHNdataset

C. He¹, M. Chandler¹, M. Recht¹, J. Charlet², T. Moulton², P. Vashi²
Abstract Number: PB0372

Evaluation of Silica Clotting Time and Hexagonal (II) Phase Phospholipid Neutralization for Lupus Anticoagulant Detection

X.T. Gao¹, R. Sumugod², K. Carmichael², P. Lindholm², L. Gillard¹, N. Lerret¹
Abstract Number: PB1066

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban at Lupus Anticoagulans Positive Patients

L. Slavik¹, J. Jacova², D. Friedecky², J. Ulehlova¹, P. Bradacova¹, A. Skoumalova³, J. Prochazkova¹, A. Hlusi¹, M. Palova¹, A. Kvasnička², E. Ivanovova², B. Pisklakova²
Abstract Number: LPB0079

Evaluation of the Different Platelet-dependent von Willebrand Factor Activity Assays Capacity to Assess the in vivo Inhibitory Effect of Caplacizumab on the VWF-platelet Interaction

P. Colpani¹, L. Baronciani¹, C. Novembrino¹, I. Mancini², G. Cozzi¹, P. De Leo¹, E. Galbiati¹, M. Boscarino², A. Artoni¹, F. Peyvandi^1,2
Abstract Number: PB1071

Evaluation of the Effect of Educational Intervention Adapted for Patients on Warfarin with Poor Anticoagulation Control: A Controlled Clinical Trial

J.M. Costa¹, M.S. Marcolino², M.F.S. Praxedes³, H.C. Torres⁴, R.P. Souza⁵, D.V. Nascimento¹, C.B. Ferreira¹, N.S. Antunes⁶, R.C. Viana¹, J.A. Araújo¹, L.A. Fernandes¹, L.d.F.M. Braga¹, A.C.R. Silva¹, H.C. Barbosa², D.D. Ribeiro⁶, M.A.P. Martins^1,2,6,7
Abstract Number: PB1304

Evaluation of the Effectiveness of Multidisciplinary Care Plans for the Perinatal Management of Women with Bleeding Disorders

N. O'Neill¹, F. Meffe^2,3, J. Baker^4,5,6, R. Martin^7,8, M. Sholzberg^{9,10,11,12,13}
Abstract Number: PB1283

Evaluation of the Efficacy and Safety of Enoxaparin Biosimilar Treatment in Our Center

M.A. Garcia Ruiz¹, P. Romero Garcia², E. Morente Constantín¹, M. Jurado Chacon¹
Abstract Number: PB0845

Evaluation of the Local Tolerability of Recombinant ADAMTS13 Following Subcutaneous Injection in Rabbits

J. Blank¹, J. McNulty¹, J. Nunes¹
Abstract Number: PB0423

Evaluation of the Lysis Timer to Investigate ‘Global Fibrinolysis Capacity’ in Plasma

M. Bareille¹, M. Hardy², B. Chatelain¹, T. Lecompte³, F. Mullier¹
Abstract Number: PB0018

Evaluation of the Need for Cytoreduction and its Potential Carcinogenicity in Children and Young Adults with Myeloproliferative Neoplasms

H.S. Choi¹, J. Hong², S.M. Hwang³, J.H. Lee⁴, Y. Ma¹, S.-A Kim⁴, J.Y. Lee⁴, J.-O. Lee⁴, S.-M. Bang⁴
Abstract Number: PB0871

Evaluation of the Sialidase Inhibitor Oseltamivir in GNE-associated Thrombocytopenia

M. Fager Ferrari¹, K.I. Smolag², E. Zetterberg¹, E. Leinoe³, T. Ek⁴, A.M. Blom², M. Rossing⁵, M. Martin²
Abstract Number: OC 24.1

Evaluation of the Tissue Factor-Independent Mechanism of Action for Eptacog Beta

J.-L. Plantier¹, S. Evans², P. Martres¹
Abstract Number: PB0906

Evaluation of von Willebrand Factor (VWF) Replacement on in vivo Angiogenesis in VWF‐deficient Mice

E. Ocran¹, K. Nesbitt², M. Hinds¹, O. Rawley², M. Bowman¹, D. Lillicrap², P. James¹
Abstract Number: PB0652

Evolution of AAV Vector Gene Therapy is Ongoing In Hemophilia. Will the Unique Features of BAY 2599023 Address the Outstanding Needs?

S.W. Pipe¹, C. Hay², J. Sheehan³, T. Lissitchkov⁴, M. Coppens⁵, H. Eichler⁶, S. Weigmann⁷, F. Ferrante⁸
Abstract Number: PB0494

Evolution of Emicizumab Plasma Concentrations and aPTT rratio in 183 Treated Patients with Severe Haemophilia A. A Real Life and Multi-centre Analysis

C. Pouplard^1,2, C. Nougier³, C. Flaujac⁴, C. Ternisien⁵, C. Auditeau⁴, M. Donnard⁶, F. Grand⁷, E. Jeanpierre⁸, V. Proulle⁹, S. Timsit¹⁰, L. Sattler¹¹, Y. Repesse¹², A. Ryman¹³, N. Hezard¹⁴, D. Lasne¹⁰, BIMHO Study Group on behlaf of GFHT
Abstract Number: OC 74.1

Evolution of the Tubulin Post-translational Modification Repertoire during Megakaryopoiesis

Q. Kimmerlin¹, S. Moog¹, L. Mallo¹, C. Strassel¹, I. Bièche^2,3, C. Gachet¹, C. Janke^4,5, F. Lanza¹
Abstract Number: PB0085

Evolution of Thrombin Generation in Pediatric Liver Transplantation

K. Regling¹, W. Hollon², K. Collins², N. Zoubi², M. Rajpurkar¹, M. Chitlur¹
Abstract Number: PB0874

Evolution over 50 Years of a Patient with Undiagnosed Gray Platelet Syndrome

A. Peleteiro Raíndo¹, E. Mellid Fernández¹, A. De Andrés y Jacob¹, A. Abuin¹, J.Á. Díaz Arias¹, E. Fontanes Trabazo¹, M.D. Vilariño López¹, A. Mosquera Orgueira¹, N. Alonso Vence¹, L. Bao Pérez¹, P. Cadahía Fernández¹, R. Ferreiro Ferro¹, P. Melero Valentín¹, M. Cid López¹, F. Vidal Pérez^2,3,4, I. Corrales Insa^2,4, J.L. Bello López¹
Abstract Number: OC 05.4

Evolutionary Adaptation of the Gamma-carboxyglutamic Acid Domain in Venom Factor X from the Australian Common Brown Snake

S. Cheng^1,2, G. Poenou^1,3, K.L. Cheung¹, M. Schreuder^1,4, M.H. Bos¹
Abstract Number: PB0468

Examination and Validation of a Patient-centric Joint Metric: “PROBLEM JOINT”; Empirical Evidence from the CHESS Paediatrics Dataset

T. Burke¹, I. Rodriguez Santana¹, P. Chowdary², R. Curtis³, K. Khair⁴, M. Laffan⁵, P. McLaughlin², D. Noone¹, B. O'Mahony⁶, J. Pasi⁷, M.W Skinner⁸, J. O'Hara¹
Abstract Number: PB0213

Excess Mortality in a Population of Vitamin K Antagonist Users during the First Wave of the COVID-19 Pandemic in the Netherlands Compared with Excess Mortality in the General Dutch Population

Q. Chen¹, M.M.A. Toorop¹, C. Visser², F.J.M. van der Meer¹, M.C. Nierman³, L. Goede⁴, H. ten Cate⁵, M.J.H.A. Kruip^2,6, W.M. Lijfering¹, S.C. Cannegieter¹, Dutch COVID & Thrombosis Coalition
Abstract Number: PB0660

Exigency: The Real-world Impact of Gene Therapy on the Lives of People with Haemophilia and their Families. An Interim Report

S. Fletcher¹, S. Chaplin², M. Holland², K. Jenner², K. Khair²
Abstract Number: PB1280

Experience with Direct Oral Anticoagulants (Doacs) for the Treatment of Cancer Associated Thrombosis

C. Aguilar¹, M. Valles², D. Condori², A.B Dueñas¹, f. Sevil¹, C. Dominguez¹
Abstract Number: LPB0054

Experimental Acetaminophen-induced Acute Liver Failure Is Associated with a Profound Consumptive Coagulopathy

D. Groeneveld¹, E.G. Bouck², L.G. Poole¹, H. Cline-Fedewa¹, K.J. Williams¹, A.S. Wolberg², J.P. Luyendyk¹
Abstract Number: LPB0055

Exploration of TFPI-mediated Inhibitory Mechanisms in Coagulation Flow Model

K. Miyazawa¹, A. Fogelson², K. Leiderman¹
Abstract Number: PB0816

Exploring the Immune-related Biomarkers for Predicting the Efficacy of Rituximab Treatment in Patients with Chronic Immune Thrombocytopenia

X. Wang^1,2,3, H. Li^1,2,3, X. Liu¹, F. Xue¹, W. Liu¹, Y. Chen¹, R. Fu¹, L. Zhang^1,2,3, R. Yang^1,2,3
Abstract Number: PB0488

Exploring the Level of Congruence between Patient- and Haematologist-reporting of Anxiety and Depression in People with Haemophilia A

T. Burke^1,2, A. Shaikh¹, G. Pedra¹, C. Hawes³, C. Camp³, J. O'Hara¹
Abstract Number: OC 09.3

Expression and Functional Studies of a Compound Heterozygous Mutation in Cis Position in the D’D3 (p.R924Q ) and D4 (p.A2178S) Domains of von Willebrand Factor (VWF)

M. Sacco¹, S. Lancellotti², M. Ferrarese³, F. Bernardi³, M. Pinotti³, M. Tardugno¹, E. De Candia², L. Di Gennaro², M. Basso², B. Giusti^4,5, M. Papi⁶, G. Perini⁶, G. Castaman⁷, R. De Cristofaro^2,1
Abstract Number: PB0965

Expression and Localization of Rab GTPase Proteins in Platelets

N. Nguyen¹, A. Melrose², E. Fellin³, I. Parra-Izquierdo¹, J. Pang¹, O. McCarty¹, J. Aslan²
Abstract Number: LPB0019

Expression of Adenovirus-mediated Human Coagulation Factor IX Gene in SD Rat Adipose Mesenchymal Stem cells

Z. Yan¹, Q. Sun¹, Y. Xie¹, L. Wang¹, S. Chen¹, W. Wu¹, Y. Yan¹, J. Yang¹
Abstract Number: PB0671

Extended Half-life Products for Perioperative Hemostasis in Major Orthopedic Surgery: Real-world Data from the LASH Study

L.P. Solimeno¹, R. Gualtierotti², J. Acquati Lozej¹, S. Arcudi², E. Biguzzi³, S.M. Siboni³, C. Carulli⁴, F. Peyvandi³
Abstract Number: PB0170

Extended Outpatient Thromboprophylaxis for Individuals with COVID-19

A. Szuman¹, Z. Kirkham^1,2, R. Price¹, S. Ahmed³, C. Macaulay⁴, K. Talks⁵, B. Greystoke⁵, K. Musgrave^2,5
Abstract Number: OC 06.2

Extended Thromboprophylaxis Following Major Abdominal/Pelvic Cancer-related Surgery: A Systematic Review and Meta-analysis of the Literature

W. Knoll¹, N. Fergusson², V. Ivankovic³, R. Auer⁴, M. Carrier³
Abstract Number: LPB0105

External Validation of IMPROVE-DD Risk Assessment Model for Venous Thromboembolism among Inpatients with COVID-19

S.K. Lin¹, M. Goldin^1,2,3, N. Kohn², M. Qiu⁴, S.L. Cohen^1,2, M.A. Barish³, E. Gianos^1,5, D. Giannis², S. Chatterjee^1,3, K. Coppa⁴, A. Diaz¹, S. Richardson^1,2, J.S. Hirsch^1,2,4, S. Ngu⁶, S. Firoozan⁶, T. McGinn^1,2, A.C. Spyropoulos^1,2
Abstract Number: PB0074

Extra-terrestrial Soils Activate Coagulation Factor XII and Manage Bleeding in a Porcine Model of Liver Laceration: Implications for Hemorrhage Control during Space Exploration

N. Ali-Mohamad^1,2, T.H. Wang^1,3, L.J. Juang^1,2,3, M. Cau^1,2,4, K. Cannon⁵, C. Kastrup^1,2,3
Abstract Number: PB0111

Extracellular Microparticles as Aortic Valves Calcification Vectors, Proof of Concepts

M. Flores Garcia¹, A. De la Peña Diaz^2,1, E. Soria Castro¹, M. Peña Duque¹, J.R. Hernández López², D. Reyes Munguía¹, M. López Granados¹, J.C. Villegas Hernández¹
Abstract Number: PB0220

Extracellular Vesicles and Citrullinated Histone H3 in Coronavirus Disease 2019 (COVID-19) Patients

L. Traby¹, M. Kollars¹, M. Kussmann¹, M. Karer¹, H. Sinkovec¹, E. Lobmeyr¹, A. Hermann¹, T. Staudinger¹, P. Schellongowski¹, B. Rössler¹, H. Burgmann¹, P.A. Kyrle¹, S. Eichinger¹
Abstract Number: PB0216

Extracorporeal Membrane Oxygenation Induces Early Alterations in Coagulation and Fibrinolysis Profiles in COVID-19 Patients with Acute Respiratory Distress Syndrome

G. Hékimian^1,2, P. Masi², M. Lejeune^1,2, G. Lebreton^1,2, J. Chommeloux², C. Desnos², M. Pineton De Chambrun², I. Martin-Toutain², A. Nieszkowska², N. Bréchot², M. Schmidt^1,2, P. Leprince^1,2, C.-E. Luyt^1,2, A. Combes^1,2, C. Frere^1,2
Abstract Number: PO104

Extracorporeally Thrombolytic Therapy of Embolic Common Carotid Artery Using Q-switched Nd:YAG Laser and Confocal Dual Pulse Electrohydraulic Shock Waves Accompanied by PESDA Microbubbles Administration

H. Mehrad^1,2, M. Farhoudi³